- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 16, 2023
Discovery & Translation
Aldena’s JAK-1-selective siRNA; an aerosol mAb for SARS-CoV-2 and more
BioCentury’s roundup of translational innovations
BioCentury | Dec 31, 2020
Distillery Therapeutics
Agonizing adiponectin receptors to treat NASH, liver fibrosis
DISEASE CATEGORY: Hepatic
INDICATION: Non-alcoholic steatohepatitis (NASH); liver fibrosis An ADIPOR1 and ADIPOR2 dual agonist based on the endogenous adipocytokine adiponectin could treat
INDICATION: Non-alcoholic steatohepatitis (NASH); liver fibrosis An ADIPOR1 and ADIPOR2 dual agonist based on the endogenous adipocytokine adiponectin could treat
BioCentury | Mar 3, 2014
Emerging Company Profile
Zebra Biologics: Antibody express
Zebra Biologics uses Scripps technology for functional antibody selection
Items per page:
1 - 4 of 4